Pay in 4 interest-free payments of $5.19 Learn more
Ships within 48 hours · Estimated delivery Aug 30 - Sep 4
10,11 Many patients with HFpEF have the obesity phenotype
FDA approved for patients 2 years and older with obesity due to BBS Help switch on the POWER of the PATHWAY IMCIVREE is the first and only treatment that targets impairment of the hypothalamic MC4R pathway, a root cause of hyperphagia and obesity due to Bardet-Biedl syndrome (BBS)
It is a dual GIP and GLP-1 receptor agonist, meaning it activates two incretin pathways simultaneously
Are there any contraindications in my medical history I should be aware of
Zinc: Zinc is essential for hair tissue growth and repair
This provides a theoretical foundation for subsequent mechanistic studies of the role of GLP-1 on Wnt/LRP5/-Catenin at the molecular level
